Literature DB >> 18305551

Making progress in treating multiple myeloma with total therapies: issue of complete remission and more.

B Barlogie, F van Rhee, J D Shaughnessy, E Anaissie, J Crowley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18305551     DOI： 10.1038/leu.2008.40

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  12 in total

1.  Going with the flow, and beyond, in myeloma.

Authors:  Bart Barlogie; Joshua Epstein; John D Shaughnessy
Journal:  Blood       Date:  2008-11-15       Impact factor: 22.113

Review 2.  How best to use new therapies in multiple myeloma.

Authors:  David Dingli; S Vincent Rajkumar
Journal:  Blood Rev       Date:  2010-04-01       Impact factor: 8.250

Review 3.  Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers.

Authors:  Mohamad Mohty; Jean-Luc Harousseau
Journal:  Haematologica       Date:  2014-03       Impact factor: 9.941

4.  Impact of Pre-transplant and Post-transplant Remission Status of Patients on Survival in Newly Diagnosed Multiple Myeloma.

Authors:  Rafiye Ciftciler; Hakan Goker; Yahya Buyukasık; Elifcan Aladag; Haluk Demiroglu
Journal:  Indian J Hematol Blood Transfus       Date:  2019-03-04       Impact factor: 0.900

5.  Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Authors:  Damien Roos-Weil; Philippe Moreau; Hervé Avet-Loiseau; Jean-Louis Golmard; Mathieu Kuentz; Stéphane Vigouroux; Gérard Socié; Sabine Furst; Jean Soulier; Steven Le Gouill; Sylvie François; Anne Thiebaut; Agnès Buzyn; Natacha Maillard; Ibrahim Yakoub-Agha; Nicole Raus; Jean-Paul Fermand; Mauricette Michallet; Didier Blaise; Nathalie Dhédin
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

6.  Curing myeloma at last: defining criteria and providing the evidence.

Authors:  Bart Barlogie; Alan Mitchell; Frits van Rhee; Joshua Epstein; Gareth J Morgan; John Crowley
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

7.  Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.

Authors:  Inger S Nijhof; Jeroen J Lammerts van Bueren; Berris van Kessel; Pascale Andre; Yannis Morel; Henk M Lokhorst; Niels W C J van de Donk; Paul W H I Parren; Tuna Mutis
Journal:  Haematologica       Date:  2014-12-15       Impact factor: 9.941

8.  Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols.

Authors:  Antje Hoering; John Crowley; John D Shaughnessy; Klaus Hollmig; Yazan Alsayed; Jackie Szymonifka; Sarah Waheed; Bijay Nair; Frits van Rhee; Elias Anaissie; Bart Barlogie
Journal:  Blood       Date:  2009-06-10       Impact factor: 22.113

9.  Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma.

Authors:  H G Kopp; S Yildirim; K C Weisel; L Kanz; W Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-22       Impact factor: 4.553

10.  Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.

Authors:  Prashant Kapoor; Shaji K Kumar; Angela Dispenzieri; Martha Q Lacy; Francis Buadi; David Dingli; Stephen J Russell; Suzanne R Hayman; Thomas E Witzig; John A Lust; Nelson Leung; Yi Lin; Steven R Zeldenrust; Arleigh McCurdy; Philip R Greipp; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  J Clin Oncol       Date:  2013-11-18       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.